| Description | Idactamab (INT-001) is a monoclonal antibody to the human amino acid transport protein ASCT2. |
| In vitro | Idactamab对多种血液癌细胞系展示了抑制效果，其IC50值在0.05至65 ng/mL范围内[2]。ASCT2（SLC1A5）是一种多通道的，依赖Na+的中性氨基酸转运蛋白，负责介导肿瘤生长和进展所需氨基酸的摄取[2]。 |
| In vivo | Idactamab 提高了三种散布性急性髓性白血病（AML）细胞系模型的生存率：TF1α（ASCT2高表达）、MOLM-13（ASCT2低表达）和M.V.411（ASCT2高表达）。相应的最小抑制浓度分别为0.05 mg/kg、0.1 mg/kg和0.1 mg/kg [1]。 |
| Target activity | Hematologic cancer cells:0.05-65 ng/mL |
| Synonyms | INT-001 |
| molecular weight | N/A |
| CAS | 2245205-37-0 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78(13_Supplement): LB-295-LB-295. 2. Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071. |